OPN expression increases with fibrosis severity and is significantly elevated in patients with stage ≥F3 NAFLD (P < 0.001), supporting its potential use as a biomarker for progressive disease (102, 103). Here, SPP1 is linked to metabolic dysfunction-associated steatotic liver disease.